Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Pancreatic Islet beta-cells are responsible for synthesizing and secreting appropriate
amounts of insulin to regulate blood glucose levels. One factor in the development of
diabetes is the loss of beta-cells. Developing treatments to prevent or restore islet
beta-cell mass (BCM) in diabetic patients is hampered by a lack of methods for the
non-invasive imaging of these cells. This study is designed to evaluate a radiolabeled
compound that binds to the pancreatic islet. The investigators will test the ability of one
promising imaging compound, 18F-9-fluoropropyl-(+)-dihydrotetrabenazine (18F-FP-DTBZ), to
measure the amount of pancreatic islet beta-cells in patients with long-standing type-1
diabetes and in age-weight-matched healthy control subjects.